ClinicalTrials.gg

Diphtheria clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 267 studies for Diphtheria across more than 10 countries. 17 are recruiting or about to start. 142 of them are mainly about Diphtheria (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
226
Status unknown
11
Recruiting
11
Active, not recruiting
7
Not yet recruiting
6
Terminated
4

Phase

Phase 3
128
Phase 4
58
Phase 2
37
Phase 1
18

Where

United States
47
China
27
Canada
17
Philippines
16
Korea, Republic of
16
Germany
14

Who develops what

Add Diphtheria to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 17 programs from 7 companies, 13 with this as their studies’ main aim; 5 with a live phase 3 study; 1 primary completion in the next 12 months. Compare CanSino Biologics, Chongqing Zhifei Biological Products and GlaxoSmithKline here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Diphtheria-Tetanus-acellular Pertussis VaccinesRecent, repeated
Evidence
  • NCT07112144 · Changchun BCHT Biotechnology Co. · Phase 3 · live · comparator · “DTaP” · registered Jun 2025
  • NCT06708286 · CanSino Biologics Inc. · Phase 3 · comparator · “Diphtheria-tetanus-acellular pertussis vaccine (DTaP)” · registered Nov 2024
  • NCT05091619 · Sinopharm · Phase 3 · live · comparator · “Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed” · registered Oct 2021
  • NCT01337167 · Merck & Co., Inc · Phase 3 · background · “DAPTACEL™” · registered Apr 2011
  • NCT00319852 · Sanofi · Phase 3 · comparator · “DTaP vaccine” · registered Apr 2006
—22 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Pentetic AcidApproved: US☆ Track1 live phase-3 study: NCT07596199GlaxoSmithKline
LBVD☆ Track1 live phase-3 study: NCT06947499LG Chem
DTacP☆ Track1 live phase-3 study: NCT07112144Changchun BCHT Biotechnology Co.
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)☆ Track1 live phase-3 study: NCT06857370CanSino Biologics Inc.

The 4 in phase 3 with the nearest primary completion, of 17 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 23 Nov 2026 est.Pentetic Acid · GlaxoSmithKline · Phase 3 main aimNCT07596199 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women — primary endpoint: Number of seropositive healthy pregnant women for anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies · 102 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diphtheria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

4studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger. 7 (64%) take children under 18. 2 (18%) are for women only and 0 (0%) for men only; 10 (91%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
101 (9%)1 (9%)
183 (27%)1 (9%)
305 (45%)3 (27%)
405 (45%)3 (27%)
504 (36%)3 (27%)
652 (18%)1 (9%)
752 (18%)1 (9%)
852 (18%)1 (9%)

Across all 267 studies, recruiting or not: 86% stop at 75 or younger and 85% at 65; 83% take children; 5% are for women only and <1% for men only; 96% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diphtheria studies take

Of 47 phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 313 mo7–21 · 47 studies13 mo7–21 · 47 studies—
Phase 422 mo8–30 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 267. Browse all 267 → or search them.